Antifungal susceptibility of Cryptococcus neoformans and Cryptococcus gattii isolates from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees in north-western India

被引:32
作者
Khan, Zia U. [1 ]
Randhawa, Harbans S.
Kowshik, Tusharantak
Chowdhary, Anuradha
Chandy, Rachel
机构
[1] Kuwait Univ, Fac Med, Dept Microbiol, Mycol Reference Lab, Kuwait, Kuwait
[2] Univ Delhi, Vallabhbhai Patel Chest Inst, Dept Med Mycol, Delhi 110007, India
关键词
Etest; fluconazole; itraconazole; voriconazole; amphotericin B;
D O I
10.1093/jac/dkm192
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: We present antifungal susceptibility data on environmental isolates of Cryptococcus neoformans (serotype A, n = 117) and Cryptococcus gattii (serotype B, n = 65) cultured from decayed wood of trunk hollows of Ficus religiosa and Syzygium cumini trees. Methods: Susceptibilities to amphotericin B, fluconazole, ketoconazole, itraconazole and voriconazole were determined by using Etest. The MICs were read after 48 h as per the guidelines provided by the manufacturer. Results: The MIC(90)s and susceptibility ranges for C. neoformans isolates were as follows: 0.094 (0.004-0.25) mg/L for amphotericin B, 4 (0.032-12) mg/L for fluconazole, 0.094 (0.004-0.75) mg/L for itraconazole, 0.064 (0.002-0.19) mg/L for ketoconazole, and 0.047 (0.006-0.125) mg/L for voriconazole, whereas for C. gattii isolates these were 0.125 (0.023-0.5) mg/L for amphotericin B, 8 (0.032-16) mg/L for fluconazole, 0.75 (0.006-2) mg/L for itraconazole, 0.125 (0.003-0.19) mg/L for ketoconazole, and 0.094 (0.004-0.125) mg/L for voriconazole. A comparison of the geometric means of MICs (mg/L) revealed that C. gattii was less susceptible than C. neoformans to amphotericin B (0.075 versus 0.051 9 P = 0.0003), fluconazole (2.9,12 versus 2.316, P = 0.003), itraconazole (0.198 versus 0.0344, P < 0.0001), ketoconazole (0.072 versus 0.037, P < 0.0001), and voriconazole (0.045 versus 0.023, P < 0.0001). Conclusions: The antifungal susceptibility data obtained in this study indicate that the occurrence of primary resistance among environmental isolates of C. neoformans serotype A and C. gattii serotype B is rare, and serotype B isolates are less susceptible than serotype A isolates.
引用
收藏
页码:312 / 316
页数:5
相关论文
共 39 条
[1]   Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents [J].
Aller, AI ;
Martín-Mazuelos, E ;
Gutiérrez, MJ ;
Bernal, S ;
Chávez, N ;
Recio, FJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (06) :997-1000
[2]  
Alves Sydney Hartz, 2001, Revista do Instituto de Medicina Tropical de Sao Paulo, V43, P267, DOI 10.1590/S0036-46652001000500006
[3]   Antifungal susceptibilities of Cryptococcus neoformans [J].
Archibald, LK ;
Tuohy, MJ ;
Wilson, DA ;
Nwanyanwu, O ;
Kazembe, PN ;
Tansuphasawadikul, S ;
Eampokalap, B ;
Chaovavanich, A ;
Reller, LB ;
Jarvis, WR ;
Hall, GS ;
Procop, GW .
EMERGING INFECTIOUS DISEASES, 2004, 10 (01) :143-145
[4]   Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis [J].
Armengou, A ;
Porcar, C ;
Mascaro, J ;
GarciaBragado, F .
CLINICAL INFECTIOUS DISEASES, 1996, 23 (06) :1337-1338
[5]   The hidden danger of primary fluconazole prophylaxis for patients with AIDS [J].
Berg, J ;
Clancy, CJ ;
Nguyen, MH .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :186-187
[6]   Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States:: 1992 to 1994 and 1996 to 1998 [J].
Brandt, ME ;
Pfaller, MA ;
Hajjeh, RA ;
Hamill, RJ ;
Pappas, PG ;
Reingold, AL ;
Rimland, D ;
Warnock, DW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) :3065-3069
[7]   Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela [J].
Calvo, BM ;
Colombo, AL ;
Fischman, O ;
Santiago, A ;
Thompson, L ;
Lazera, M ;
Telles, F ;
Fukushima, K ;
Nishimura, K ;
Tanaka, R ;
Myiajy, M ;
Moretti-Branchini, ML .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (06) :2348-2350
[8]  
Casadevall A, 1998, CRYPTOCOCCUS NEOFORM, DOI DOI 10.1128/9781555818241
[9]   In vitro activity of amphotericin B, fluconazole and voriconazole against 162 Cryptococcus neoformans isolates from Africa and Cambodia [J].
Chandenier, J ;
Adou-Bryn, KD ;
Douchet, C ;
Sar, B ;
Kombila, M ;
Swinne, D ;
Thérizol-Ferly, M ;
Buisson, Y ;
Richard-Lenoble, D .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2004, 23 (06) :506-508
[10]   Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan [J].
Chen, YC ;
Chang, SC ;
Shih, CC ;
Hung, CC ;
Luh, KT ;
Pan, YS ;
Hsieh, WC .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2000, 36 (03) :175-183